期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 23, 期 1, 页码 121-131出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2010.01.007
关键词
chronic lymphocytic leukaemia; NF-kappa B; drug resistance
类别
资金
- CALGB Foundation
- D. Warren Brown Foundation
- Leukemia and Lymphoma Society
- National Cancer Institute [P01 CA95426, T325CA009338, T32 CA106196, P01 CA101956]
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signalling pathway is constitutively active in a variety of cancers, including chronic lymphocytic leukaemia (CLL). The importance of this signalling pathway identifies it as a prime therapeutic target; however, the complexity and potential side effects of inhibiting NF-kappa B have thus far made the clinical use of NF-kappa B inhibitors a relatively unexplored resource in this disease. This article discusses the role of NF-kappa B in CLL as a common crossroad for pathways promoting drug resistance in CLL. We provide the background on how this pathway contributes to both spontaneous and drug-induced apoptosis. Potential new avenues to regulate this pathway in CLL are also discussed. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据